Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Study Completion Date

2007-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Idiopathic pulmonary fibrosis(IPF) is chronic progressive fibrosing lung disease of unknown cause. There is no effective therapy yet for this disease and the mean survival in most reports is about 3 years after the diagnosis. Because of the stiff fibrosis of the lung, pulmonary hypertension is the late complication of IPF and its development heralds a very poor outcome of the patients. For the primary pulmonary hypertension, recently the effective drugs have been available. However, there is no study about the efficacy of these drugs in the patients with pulmonary hypertension secondary to pulmnary fibrosis, and the aim of this trial is to study the safty and efficacy of "Iloprost," one of the safe and effective drugs in primary pulmonary hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

NCT00109681

Pulmonary Fibrosis Pulmonary Hypertension

COMPLETED PHASE2

Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction

NCT03620526

Heart Failure With Normal Ejection Fraction

UNKNOWN PHASE4

Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease

NCT01319045

Pulmonary Arterial Hypertension Congenital Heart Disease Eisenmenger's Syndrome

TERMINATED NA

Iloprost Effects on Gas Exchange and Pulmonary Mechanics

NCT01274481

Acute Respiratory Distress Syndrome Acute Lung Injury Pulmonary Hypertension

COMPLETED PHASE1

Iloprost Power 15 in Pulmonary Arterial Hypertension

NCT00709956

Pulmonary Arterial Hypertension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Prospective open labeled observational study
* Subjects: About 15 patients with secondary pulmonary hypertension due to IPF or pulmonary fibrosis associated with collagen vascular diseases.
* Method: 3 month trial of inhaled iloprost. Check the safty and measure the pulmonary arterial pressure by right heart catheterization, exercise capacity by 6 minute walking test, echocardiography, and quality of life questionnaires before and after the trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Fibrosis Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iloprost inhalation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of idiopathic pulmonary fibrosis or fibrotic NSIP according to American Thoracic Society and European Respiratory Society guidelines by biopsy and diagnosis of pulmonary fibrosis associated with connective tissue disease.
* Mean pulmonary artery pressure over 30mmHg.
* NYHA functional class II to IV

Exclusion Criteria

* Suffering lung diseases other than pulmonary fibrosis (COPD, Pulmonary Thromboendarterectomy ).
* Administration of prostanoids, bosentan, beta- blocker or phosphodiesterase5 inhibitor.
* Dosage adjustment of calcium channel blockers within 6 weeks.
* Resting pulmonary capillary wedge pressure over 15mmHg.
* Bleeding tendency.
* Bilirubin level above 3mg/dl or creatinine clearance level below 30ml/min.
* Unstable angina pectoris, myocardial infarction or severe arrhythmia within 6 months.
* Cerebrovascular accident within 6 months.
* Present lung infection.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No